Conference item icon

Conference item

Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study

Subtitle:
abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1111/all.13539

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Subgroup:
NDM Strategic
Oxford college:
St Edmund Hall
ORCID:
0000-0002-4288-5973
Expand authors...
Publisher:
Wiley Publisher's website
Volume:
73
Issue:
S105
Pages:
463-464
Publication date:
2018-08-14
DOI:
ISSN:
0105-4538 and 1398-9995
Pubs id:
pubs:915440
URN:
uri:595ce41f-d52f-4eb1-b2ef-ad8917902cea
UUID:
uuid:595ce41f-d52f-4eb1-b2ef-ad8917902cea
Local pid:
pubs:915440

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP